Matrix Games Forums

ORIGINAL: mind_messing

ORIGINAL: RangerJoe

ORIGINAL: mind_messing




The person.

Curious as to your claim that the CDC has a political agenda, that's news to me, not being from the US. Would you mind expanding on it?

Every governmental entity has a political agenda. More money, larger budgets, more control => more power. The CDC apparently stopped other entities in the United States from developing tests for the Corona virus, that meant that any tests had to come from the CDC. Meaning that the CDC could ask for more money, more employees, and hence, more power.

Interesting. Have you a source for that?

ORIGINAL: RangerJoe

ORIGINAL: mind_messing

ORIGINAL: RangerJoe




Every governmental entity has a political agenda. More money, larger budgets, more control => more power. The CDC apparently stopped other entities in the United States from developing tests for the Corona virus, that meant that any tests had to come from the CDC. Meaning that the CDC could ask for more money, more employees, and hence, more power.

Interesting. Have you a source for that?

It is the way that things work in any business entity, governmental entity, or other organizations. Offices with a window, corner offices are even more prestigious. A secretary for just one person and not shared, how many assistants (if any) are all signs of power. Even if they make the workload heavier and are not needed. I suggest that you take some college business courses for the sources. Don't forget to take simple economic courses as well. Not to mention higher level courses if needed.

ORIGINAL: PaxMondo

I don't know that they stopped them, but I do know that we will be importing Swiss ones and as I understand it, they will be license built in the US shortly.

ORIGINAL: Canoerebel

Good point on false-positives vs. false-negatives, Pax.

Question: I understand (I think) why the lack of testing is such a concern. If the disease has escaped containment, is running rampant and undetected in the general population, should we very soon see (or should have already seen?) an exponential growth in people admitted in extremis and in the number of deaths?

There can be a lag between onset and full-blown maturity, but whether there is adequate testing or not, should we see exponential increases in admissions and mortalities? Especially in states like Washington, California, New York, Florida?

The numbers are up but (to my untrained eye) the deaths are much less than I would expect.

If that's true, in turn, is it due to the quality of medical care, the actual rate of mortality, a combination of these and other things?

In the USA today, the number of deaths is up by six. We're now two weeks into this. Given what I'm hearing and seeing, I'd expect much higher numbers, either now or soon.

ORIGINAL: durnedwolf

Hey RangeJoe,

In regards to the arthritis medications info and link you posted - I wanted to say thanks. My wife contacted her doctor to ask about any known complications for people using her medication and regimen for rheumatoid arthritis. The doctor basically said there wasn't a strong sample size nor many within his network that had any working experience with the virus yet.

In the end, he basically told her to try extra-hard not to catch the virus... <wry grin>.

ORIGINAL: mind_messing

ORIGINAL: RangerJoe

ORIGINAL: mind_messing




Interesting. Have you a source for that?

It is the way that things work in any business entity, governmental entity, or other organizations. Offices with a window, corner offices are even more prestigious. A secretary for just one person and not shared, how many assistants (if any) are all signs of power. Even if they make the workload heavier and are not needed. I suggest that you take some college business courses for the sources. Don't forget to take simple economic courses as well. Not to mention higher level courses if needed.

You've misunderstood - a source for your claim that the CDC stopped manufacture of testing kits.

With a vaccine for COVID-19 still a long way from being realized, Johns Hopkins immunologist Arturo Casadevall is working to revive a century-old blood-derived treatment for use in the United States in hopes of slowing the spread of the disease.

With the right pieces in place, the treatment could be set up at Johns Hopkins University in Baltimore within a matter of weeks, Casadevall says.

The technique uses antibodies from the blood plasma or serum of people who have recovered from COVID-19 infection to boost the immunity of newly infected patients and those at risk of contracting the disease. These antibodies contained in the blood's serum have the ability to bind to and neutralize SARS-CoV-2, the virus that causes COVID-19. Casadevall—a Bloomberg Distinguished Professor of molecular microbiology and immunology and infectious diseases at the Johns Hopkins Bloomberg School of Public Health and School of Medicine—published a paper on the proposal today in The Journal of Clinical Investigation.

"Deployment of this option requires no research or development," he says. "It could be deployed within a couple of weeks since it relies on standard blood-banking practices."

In this case, physicians would ask patients who recover from COVID-19 to donate their blood, from which sera would be isolated. After processing the serum and removing other toxins or trace illnesses, it can be injected into sick patients and those at risk of contracting the disease. The procedure for isolating serum or plasma is a long-established technology that can be performed using equipment normally found in hospitals and blood-banking facilities, and recent advances make it as safe as a blood transfusion, Casadevall says.

Experts around the U.S. are rushing to implement the treatment in several different areas, including New York City, Casadevall says. Doctors in Shanghai have already used the plasma therapy with newly infected coronavirus patients in China and have reported promising early results. Japan's largest drugmaker, Takeda Pharmaceuticals, has also begun testing the therapy.

ORIGINAL: Kull

A treatment for the uninfected - not a vaccine but a procedure which could dramatically slow the spread of the disease - could be just weeks away:

With a vaccine for COVID-19 still a long way from being realized, Johns Hopkins immunologist Arturo Casadevall is working to revive a century-old blood-derived treatment for use in the United States in hopes of slowing the spread of the disease.

With the right pieces in place, the treatment could be set up at Johns Hopkins University in Baltimore within a matter of weeks, Casadevall says.

The technique uses antibodies from the blood plasma or serum of people who have recovered from COVID-19 infection to boost the immunity of newly infected patients and those at risk of contracting the disease. These antibodies contained in the blood's serum have the ability to bind to and neutralize SARS-CoV-2, the virus that causes COVID-19. Casadevall—a Bloomberg Distinguished Professor of molecular microbiology and immunology and infectious diseases at the Johns Hopkins Bloomberg School of Public Health and School of Medicine—published a paper on the proposal today in The Journal of Clinical Investigation.

"Deployment of this option requires no research or development," he says. "It could be deployed within a couple of weeks since it relies on standard blood-banking practices."

In this case, physicians would ask patients who recover from COVID-19 to donate their blood, from which sera would be isolated. After processing the serum and removing other toxins or trace illnesses, it can be injected into sick patients and those at risk of contracting the disease. The procedure for isolating serum or plasma is a long-established technology that can be performed using equipment normally found in hospitals and blood-banking facilities, and recent advances make it as safe as a blood transfusion, Casadevall says.

Experts around the U.S. are rushing to implement the treatment in several different areas, including New York City, Casadevall says. Doctors in Shanghai have already used the plasma therapy with newly infected coronavirus patients in China and have reported promising early results. Japan's largest drugmaker, Takeda Pharmaceuticals, has also begun testing the therapy.

ORIGINAL: obvert

This has been done already in China. One female doctor who recovered donated her plasma for this cause.

https://www.nytimes.com/interactive/202 ... -life.html

[font="Trebuchet MS"]The Chinese government has urged recovered patients to donate plasma, which experts say contains antibodies that could be used to treat the sick. Ms. Deng contacted a local blood bank soon after getting home.

She plans to go back to work as soon as the hospital allows it.

“It was the nation that saved me,” she said. “And I think I can pay it back to the nation.”[/font]

It seems they've been doing this since early February treat some patients at least.

https://time.com/5784286/covid-19-china ... treatment/

[font="Trebuchet MS"]China National Biotec Group Co. has been using this plasma, which contains highly potent antibodies, to treat more than 10 seriously ill patients since Feb. 8, the company said in an statement on its official WeChat account Thursday night. It claimed that those receiving the treatment improved within 24 hours, with reduced inflammation and viral loads along with better oxygen levels in the blood.[/font]